What if the future of HER2‐positive breast cancer patients was written in miRNAs? An exploratory analysis from NeoALTTO study-Reference-Cited by-同舟云学术

What if the future of HER2‐positive breast cancer patients was written in miRNAs? An exploratory analysis from NeoALTTO study

Published:2021-12-17 Issue:2 Volume:11 Page:332-339
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Medicine

Author:

Pizzamiglio Sara¹,Cosentino Giulia²,Ciniselli Chiara M.¹,De Cecco Loris³^ORCID,Cataldo Alessandra²,Plantamura Ilaria²,Triulzi Tiziana²,El‐abed Sarra⁴^ORCID,Wang Yingbo⁵,Bajji Mohammed⁶,Nuciforo Paolo⁷,Huober Jens⁸,Ellard Susan L.⁹,Rimm David L.¹⁰,Gombos Andrea⁶,Daidone Maria Grazia¹¹,Verderio Paolo¹,Tagliabue Elda²,Di Cosimo Serena¹¹^ORCID,Iorio Marilena V.²^ORCID

Affiliation:

1. Bioinformatics and Biostatistics Unit Department of Applied Research and Technological Development Fondazione IRCCS Istituto Nazionale dei Tumori Milan Italy

2. Molecular Targeting Unit Department of Research Fondazione IRCCS Istituto Nazionale dei Tumori Milan Italy

3. Integrated Biology Platform Department of Applied Research and Technological Development Fondazione IRCCS Istituto Nazionale dei Tumori Milan Italy

4. Breast International Group (BIG) Brussels Belgium

5. Novartis Pharma AG Basel Switzerland

6. Institute Jules Bordet (IJB) Brussels Belgium

7. Molecular Oncology Group Vall d'Hebron Institute of Oncology (VHIO) Barcelona Spain

8. Breast Center Cantonal Hospital St. Gallen Switzerland

9. BC Cancer Kelowna British Columbia Canada

10. Department of Pathology Yale University School of Medicine New Haven Connecticut USA

11. Biomarkers Unit Department of Applied Research and Technological Development Fondazione IRCCS Istituto Nazionale dei Tumori Milan Italy

Funder

Ministero della Salute

Publisher

Wiley